OSLM
Outcome Studies
in Laboratory Medicine
guest
👤
Learn more about this platform
c
Categories
p
Projects
Highlighted
Trial protocol
Study Design
RCT
Cluster RCT
Observational
Model
Meta-analysis
Review
Guideline
Outcomes
Change patient management
Clinical outcomes
Economics
Operational efficiencies
Patient-centeredness
Safety
Guide Policy Making
Other
Uncategorized
Antibiotic Guidance
ACT Guided Heparinization
Cancer
COVID-19
Cardiovascular Disease
Diabetes
HIV POCT
Inflammatory Bowel Disease
Liver Disease
Kidney Disease
Newborn Screening
MALDI-TOF MS For Microorganism Identification
Preeclampsia
Therapeutic drug monitoring
Pharmacogenetic and Pharmacogenomics
Viscoelastic Testing
Please contact us for any suggestions
Zhen Zhao
Smeralda Skenderaj
Search
Search
Project:
Inflammatory Bowel Disease
Categories:
Clinical outcomes
Economics
5 Publications
found
Cost-Effectiveness of Tight Control for Crohn’s Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective.
b
Journal of the Canadian Association of Gastroenterology
August 1, 2022
p
Inflammatory Bowel Disease
c
Clinical outcomes
Economics
Model
A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn’s Disease.
b
The American journal of gastroenterology
August 1, 2021
p
Inflammatory Bowel Disease
c
Clinical outcomes
Economics
Highlighted
Model
Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn’s Disease.
b
Applied health economics and health policy
July 1, 2021
p
Inflammatory Bowel Disease
c
Clinical outcomes
Economics
Model
Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis.
b
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
June 1, 2021
p
Inflammatory Bowel Disease
c
Clinical outcomes
Economics
Highlighted
Model
Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
b
Gut
April 1, 2020
p
Inflammatory Bowel Disease
c
Clinical outcomes
Economics
Model